Long‐Term Pooled Safety Analysis of Palbociclib in Combination with Endocrine Therapy for Hormone Receptor‐Positive/Human Epidermal Growth Factor Receptor 2‐Negative Advanced Breast Cancer: Updated Analysis with up to 5 Years of Follow‐Up

BACKGROUND: Previous studies demonstrated the tolerability of palbociclib plus endocrine therapy (ET). This analysis evaluated safety based on more recent cutoff dates and a longer palbociclib treatment exposure. PATIENTS AND METHODS: Data were pooled from three randomized studies of patients with h...

पूर्ण विवरण

में बचाया:
ग्रंथसूची विवरण
में प्रकाशित:Oncologist
मुख्य लेखकों: Finn, Richard S., Rugo, Hope S., Gelmon, Karen A., Cristofanilli, Massimo, Colleoni, Marco, Loi, Sherene, Schnell, Patrick, Lu, Dongrui R., Theall, Kathy Puyana, Mori, Ave, Gauthier, Eric, Bananis, Eustratios, Turner, Nicholas C., Diéras, Véronique
स्वरूप: Artigo
भाषा:Inglês
प्रकाशित: John Wiley & Sons, Inc. 2021
विषय:
Breast Cancer
ऑनलाइन पहुंच:https://ncbi.nlm.nih.gov/pmc/articles/PMC8100571/
https://ncbi.nlm.nih.gov/pubmed/33486783
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/onco.13684
टैग : टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!

समान संसाधन